Roche launches Phase II TARBELA-AD trial of NLRP3 inhibitor in AD

17/11/2026

Roche has initiated a new Phase II clinical trial, TARBELA-AD, to evaluate its investigational oral NLRP3 inhibitor RG6434 in people with early symptomatic Alzheimer’s disease (AD). The study design was presented in a poster at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. The poster, entitled “Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease”, outlines the rationale and methodology of the trial.
TARBELA-AD is a global, multicentre, randomised, double-blind and placebo-controlled Phase II study designed to assess the efficacy and safety of RG6434 in adults with early symptomatic AD. Participants are randomised to receive either a low dose of RG6434, a high dose of RG6434, or placebo over a 72-week treatment period. The study plans to enrol 450 participants across 17 countries. Recruitment has already started in the US, Australia and several European countries. Primary completion is currently estimated for November 2029.
The primary endpoint is the change from baseline to Week 72 in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a composite measure of cognitive and functional decline. Secondary endpoints include changes in the Alzheimer's Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog-13) and the Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL), alongside the incidence of adverse events, changes in the Columbia-Suicide Severity Rating Scale (C-SSRS), and the assessment of RG6434's plasma pharmacokinetic profile.
https://www.neurologylive.com/view/roche-launches-phase-2-tarbela-ad-trial-nlrp3-inhibitor-alzheimer-disease